<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <Volume-Issue>Volume 2; Issue 1</Volume-Issue>
      <Season>(Jan-Feb, 2021)</Season>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Tacrolimus-Induced Post-Transplant Diabetes Mellitus: A Case Report</ArticleTitle>
      <Abstract>A 38-year-old man presents to hospital in diabetic ketoacidosis (DKA) after developing presumed post-transplant diabetes mellitus (PTDM) following an orthotopic heart transplant due to fulminant viral myocarditis. Amongst his immunosuppressant therapy he took tacrolimus, which is commonly used after solid organ transplantation. Whilst it is very effective in preventing rejection, it has a range of side effects including an increased risk of PTDM. Depending on the organ transplanted, PTDM can affect between 10 to 40% of solid organ transplants and patients taking tacrolimus have been shown to be more likely to develop this side effect (Chowdhury, 2019). During his admission with myocarditis, he also developed Covid-19, which has been anecdotally associated with the development of new-onset diabetes and increased presentations of DKA.</Abstract>
      <Keywords>Tacrolimus,Post-Transplant Diabetes Mellitus,Diabetic Ketoacidosis</Keywords>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=9305&amp;title=Tacrolimus-Induced Post-Transplant Diabetes Mellitus: A Case Report</Abstract>
        <References>Biddle K and Ahmed S. Tacrolimus. Practical Diabetes 2019; 36: 33-35.&#13;
Chakkera H and Mandarino L. Calcineurin Inhibition and New-Onset Diabetes Mellitus After Transplantation. Transplantation Journal 2013; 95: 647-652.&#13;
Chakkera H, Kudva Y, Kaplan B. Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus. Clin Pharmacol Ther 2016; 101: 114-120.&#13;
Chowdhury T. Post-transplant diabetes mellitus. Clinical Medicine 2019; 19: 392-395.&#13;
Ekberg H, Tedesco-Silva H, Demirbas A, Vand;iacute;tko and;Scaron;, Nashan B, Gand;uuml;rkan A, Margreiter R, Hugo C, Grinyand;oacute; JM, Frei U, Vanrenterghem Y. Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation. N Engl J Med 2007; 357: 2562-2575.&#13;
Hussain M, Jabeen N, Raza F, Shabbir S, Baig AA, Amanullah A, Aziz 0042. Structural variations in human ACE2 may influence its binding with SARS?CoV?2 spike protein. J Med Virol 2020; 92: 1580-1586.&#13;
Pereira MJ, Palming J, Rizell M, Aureliano M, Carvalho E, Svensson MK, Eriksson JW. Cyclosporine A and Tacrolimus Reduce the Amount of GLUT4 at the Cell Surface in Human Adipocytes: Increased Endocytosis as a Potential Mechanism for the Diabetogenic Effects of Immunosuppressive Agents. J Clin Endocrinol Metab 2014; 99: E1885-E1894.&#13;
Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, Mingrone G, Boehm B, Cooper ME, Chai Z, Del Prato S. New-Onset Diabetes in Covid-19. N Engl J Med 2020; 383: 789-790.&#13;
Unsworth R, Wallace S, Oliver NS, Yeung S, Kshirsagar A, Naidu H, Kwong RM, Kumar P, Logan KM. New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care 2020; 43: e170-171.&#13;
Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010; 47: 193-199.</References>